Pharmaceuticals Ltd.


Executive Staff


Executive Staff Dr. I. Shamir Leibovitz: President, founder, Chief Medical Officer, inventor of Preventerm & Inducterm 

Director of Clinical Trials:

Prof. Eliezer Shalev 

Associate Director of Clinical Trials:

Prof. Daniel Siedman

“BeyondTech” – Marketing solutions. – Investor Relations ( outsource )

E-mail:   +972 – 058 735 3533

Board of Advisors:

Prof. Robert Goldenberg

Prof. Phillip Robert Bennet

Prof. Gian Carlo Di Renzo


Various scientific case reports on the use of the Preventerm source molecule report no adverse side effects to the mother or infant

Initial tests of Preventerm have shown a 90% efficacy rate in preventing preterm labor – overwhelmingly more effective than any of the currently available treatment modalities

Preventerm stands to decrease the overall expense of preterm infant health care and will reduce infant mortality as well as post-natal complications considerably

We intend to generate revenue through joint and/or strategic collaborations with large pharmaceutical and biotechnology companies in order to further develop our products, jointly facilitate regulatory approval, and subsequently to bring our products to the global markets

A unique investment opportunity: Patented and patent-pending breakthrough drugs Direct solution to a pressing market need Vast expertise in the OB/Gyn industry Several discrete multi-billion dollar markets Strategic value to large pharmaceutical companies